Sanofi, Regeneron Announce Positive Trials for Cholesterol Drug
August 29 2016 - 2:43AM
Dow Jones News
By Matthew Dalton
PARIS--Sanofi and U.S. drugmaker Regeneron Pharmaceuticals, Inc.
Monday said that their jointly developed cholesterol drug Praluent
met targets in a clinical trial, reducing cholesterol in people
with a hereditary high-cholesterol disorder and lowering the need
for an expensive procedure to cut cholesterol levels.
Praluent had been approved by regulators last year, on condition
that the companies continued studies with human subjects. The drug
is intended for patients with high cholesterol who don't respond to
statins, the drugs most commonly prescribed to treat the
condition.
Write to Matthew Dalton at matthew.dalton@wsj.com
(END) Dow Jones Newswires
August 29, 2016 03:28 ET (07:28 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.